NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
Clinical Trials
128 trialsNCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04143711 2026-03-18
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
NCT04423029 2026-03-18
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Phase 1 Completed
NCT07192926 2026-02-20
SARCO-CTI
Ankara Etlik City Hospital
Completed
NCT02523469 2026-02-17
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Medical University of South Carolina
Phase 1/2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03575793 2026-01-20
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT07141563 2026-01-07
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
Bristol-Myers Squibb
Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03469960 2025-11-18
DICIPLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Completed
NCT02812667 2025-11-12
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Phase 1 Completed
NCT02823990 2025-11-10
TG4010 and Nivolumab in Patients With Lung Cancer
University of California, Davis
Phase 2 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed
NCT03573947 2025-10-14
TOP1705
Duke University
Phase 2 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03383302 2025-08-01
STILE
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT04026412 2025-07-24
CheckMate73L
Bristol-Myers Squibb
Phase 3 Completed
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03063450 2025-04-10
CONFIRM
University of Southampton
Phase 3 Completed
NCT04943900 2025-04-09
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02582125 2025-03-24
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 2 Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT04177953 2025-02-06
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04263051 2025-02-05
Optim-UCPVax
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT04350463 2025-01-22
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
Phase 2 Completed
NCT03667716 2025-01-17
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
Phase 1 Completed
NCT04731467 2024-12-27
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
Phase 1/2 Completed
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT06735781 2024-12-16
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
Bristol-Myers Squibb
Completed
NCT02175017 2024-12-09
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 2 Completed
NCT03081689 2024-12-04
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Spanish Lung Cancer Group
Phase 2 Completed
NCT02613507 2024-11-19
CheckMate 078
Bristol-Myers Squibb
Phase 3 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02046733 2024-11-08
STIMULI
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03958045 2024-10-22
Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma
University of Kentucky
Phase 2 Completed
NCT03583086 2024-10-08
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT03195491 2024-07-18
CheckMate870
Bristol-Myers Squibb
Phase 3 Completed
NCT03502330 2024-07-03
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
Phase 1 Completed